文献速递骨软组织肉瘤与黑色素瘤

转移性黑色素瘤中基于PD-1免疫治疗的早期应答与晚期应答比较

Early versus late response to PD-1-based immunotherapy in metastatic melanoma.
PubMed 文献 · Eur J Cancer · 2024-08-23

该前瞻性多中心真实世界DeCOG研究ADOREG-TRIM(NCT05750511)纳入522例接受PD-1基础免疫治疗的不可切除IV期黑色素瘤患者,比较早期应答(前3个月内达完全或部分缓解)、晚期应答、疾病稳定与无应答者的特征与生存。早期应答仅占8.2%,且早期应答者在缓解持久性和生存方面不优于晚期应答者。

要点

  • 522例中早期应答8.2%(n=43),晚期应答19.0%(n=99),疾病稳定37.0%(n=193),无应答35.8%(n=187)。
  • 肿瘤PD-L1阳性(RR=1.99,95%CI 1.14-3.46,p=0.015)与正常血清CRP(RR=1.59,95%CI 0.93-2.70,p=0.036)与早期应答独立相关。
  • 早期应答者无进展生存与总生存均不优于晚期应答者。

核心结论

  • 不到10%的转移性黑色素瘤患者在接受基于PD-1的免疫治疗前3个月内获得早期应答,且早期应答者在缓解持久性和生存方面不优于晚期应答者。

研究设计与样本

  • 从前瞻性多中心真实世界DeCOG研究ADOREG-TRIM(NCT05750511)中选取接受基于PD-1的免疫治疗(任何治疗线)的不可切除IV期黑色素瘤患者,共522例。

主要发现

  • 522例中早期应答8.2%(n=43)、晚期应答19.0%(n=99)、疾病稳定37.0%(n=193)、无应答35.8%(n=187)。
  • 经年龄和性别校正的多变量对数二项回归显示,肿瘤PD-L1阳性(RR=1.99,95%CI 1.14-3.46,p=0.015)和正常血清CRP(RR=1.59,95%CI 0.93-2.70,p=0.036)与相较于无应答者获得早期应答独立相关。
  • 早期应答者的中位无进展生存46.0个月(95%CI 19.1;NR)、中位总生存47.8个月(95%CI 36.9;NR);晚期应答者中位无进展生存和总生存均为NR(95%CI NR;NR);疾病稳定者中位无进展生存8.1个月(7.0;10.4)、中位总生存35.4个月(29.2;NR);无应答者中位无进展生存2.0个月(95%CI 1.9;2.1)、中位总生存6.1个月(95%CI 4.6;8.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early, late and non-response to ICI and analysis of survival outcomes in a real-world patient cohort. METHODS: Patients who received PD-1-based immunotherapy for non-resectable stage-IV melanoma in any therapy line were selected from the prospective multicenter real-world DeCOG study ADOREG-TRIM (NCT05750511). Patients showing complete (CR) or partial (PR) response already during the first 3 months of treatment (Early Responders, EarlyR) were compared to patients showing CR/PR at a later time (Late Responders, LateR), a stable disease (SD) and to patients showing progressive disease (Non-Responders, NonR). RESULTS: Of 522 patients, 8.2 % were EarlyR (n = 43), 19.0 % were LateR (n = 99), 37.0 % had a SD (n = 193) and 35.8 % were NonR (n = 187). EarlyR, LateR and SD patients had comparable baseline characteristics. Multivariate logbinomial regression analyses adjusted for age and sex revealed positive tumor PD-L1 (RR=1.99, 95 %-CI=1.14-3.46, p = 0.015), and normal serum CRP (RR=1.59, 95 %-CI=0.93-2.70, p = 0.036) as independently associated with the achievement of an early response compared to NonR. The median progression-free and overall survival was 46.0 months (95 % CI 19.1; NR) and 47.8 months (95 %-CI 36.9; NR) for EarlyR, NR (95 %-CI NR; NR) for LateR, 8.1 months (7.0; 10.4) and 35.4 months (29.2; NR) for SD, and 2.0 months (95 %-CI 1.9; 2.1) and 6.1 months (95 %-CI 4.6; 8.8) for NonR patients. CONCLUSION: Less than 10 % of metastatic melanoma patients achieved an early response during the first 3 months of PD-1-based immunotherapy. Early responders were not superior to late responders in terms of response durability and survival.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lodde GC, Zhao F, Herbst R, et al. Early versus late response to PD-1-based immunotherapy in metastatic melanoma. Eur J Cancer. 2024. PMID: 39213786. doi:10.1016/j.ejca.2024.114295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。